Diaceutics (7DC) Stock Price & Analysis
7DC Stock Chart & Stats
- Day’s Range
- EUR 2.32 - EUR 2.38
- 52-Week Range
- EUR 1.39 - EUR 2.40
- Previous Close
- EUR 2.34
- Volume
- 0
- Average Volume (3M)
- 343
- Market Cap
- EUR 206.39M
- Enterprise Value
- EUR 117.62M
- Total Cash (Recent Filing)
- EUR 8.10M
- Total Debt (Recent Filing)
- EUR 2.09M
- Price to Earnings (P/E)
- ―
- Beta
- 0.52
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage and a sizable equity base provide financial flexibility for ongoing operations and investment. Stable, modest debt reduces balance-sheet pressure and leaves the company better positioned to fund growth or absorb business volatility over the next several quarters.
Meaningful Revenue Scaling
Growth continuing from a larger revenue base indicates that Diaceutics is expanding its commercial activity rather than relying solely on an early-stage starting point. Sustained scaling can improve operating leverage and strengthen the platform’s position in precision-medicine diagnostics.
Return To Positive Cash Generation
Positive operating and free cash flow in 2025 improves the company’s ability to support operations internally and reduces reliance on external funding. The rebound is especially important because free cash flow was negative in the prior two years, showing recent progress in cash generation.
Bears Say
Operating Profitability Remains Unproven
The return to a small net profit has not yet translated into consistent operating profitability. A slightly negative operating result and a very thin net margin leave limited room for execution setbacks, making durable earnings conversion an important unresolved business issue.
Volatile Profitability History
The changing profitability pattern suggests that earnings performance remains sensitive to the company’s operating scale and spending profile. Until margins stabilize across reporting periods, revenue growth may not reliably produce durable operating earnings or predictable financial performance.
Inconsistent Cash Conversion
Although cash generation improved in 2025, the earlier pattern of large free cash outflows and low operating cash flow indicates uneven cash conversion and spending discipline. This history could constrain internally funded growth if weaker conversion reappears over coming quarters.
Diaceutics News
7DC FAQ
What was Diaceutics’s price range in the past 12 months?
What is Diaceutics’s market cap?
When is Diaceutics’s upcoming earnings report date?
How were Diaceutics’s earnings last quarter?
Is Diaceutics overvalued?
Does Diaceutics pay dividends?
What is Diaceutics’s EPS estimate?
How many shares outstanding does Diaceutics have?
What happened to Diaceutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Diaceutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Diaceutics
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Ryan Keeling
- Employees
- 205
- Website
- www.diaceutics.com
- Address
- Building Two, Belfast, AT, BT9 6GW, GB
Diaceutics (7DC) Earnings & Revenues
7DC Earnings Call
Earnings Call SentimentPositive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.
View all DE:7DC earnings summaries7DC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 12 | 0 | 0 |